Bronte Capital Management Pty Ltd. Has $144.06 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bronte Capital Management Pty Ltd. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 137,042 shares of the biopharmaceutical company's stock after selling 2,412 shares during the period. Regeneron Pharmaceuticals makes up approximately 12.5% of Bronte Capital Management Pty Ltd.'s holdings, making the stock its 3rd biggest holding. Bronte Capital Management Pty Ltd. owned 0.12% of Regeneron Pharmaceuticals worth $144,064,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in REGN. Stephens Consulting LLC purchased a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $26,000. Sachetta LLC raised its stake in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 10 shares during the last quarter. Crewe Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at about $28,000. Lynx Investment Advisory purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $33,000. Finally, Family Firm Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $33,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

REGN has been the topic of several recent research reports. BMO Capital Markets lowered their target price on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating on the stock in a report on Friday, November 1st. Guggenheim increased their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a "buy" rating in a research report on Friday, August 2nd. Piper Sandler cut their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. StockNews.com lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Monday, November 4th. Finally, Barclays dropped their target price on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating on the stock in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating and eighteen have issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $1,107.25.

Insider Buying and Selling

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business's stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 7.48% of the stock is owned by insiders.

Regeneron Pharmaceuticals Trading Down 0.5 %

Shares of NASDAQ:REGN traded down $4.09 during trading on Tuesday, hitting $821.59. 195,929 shares of the company's stock were exchanged, compared to its average volume of 521,593. The firm has a 50-day moving average price of $1,014.52 and a two-hundred day moving average price of $1,037.74. Regeneron Pharmaceuticals, Inc. has a 1-year low of $784.96 and a 1-year high of $1,211.20. The firm has a market cap of $90.28 billion, a P/E ratio of 20.43, a PEG ratio of 3.13 and a beta of 0.15. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.